Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 64

1.

Carfilzomib-related acute kidney injury.

Jhaveri KD, Chidella S, Varghese J, Mailloux L, Devoe C.

Clin Adv Hematol Oncol. 2013 Sep;11(9):604-5. No abstract available.

PMID:
24518527
[PubMed - in process]
2.

Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib.

Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee DM, Kim KB, Lee W.

Mol Pharm. 2012 Aug 6;9(8):2197-205. doi: 10.1021/mp300044b. Epub 2012 Jul 13.

PMID:
22734651
[PubMed - in process]
Free PMC Article
3.

Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.

Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, Bennett MK, Molineaux CJ, Kirk CJ.

Drug Metab Dispos. 2011 Oct;39(10):1873-82. doi: 10.1124/dmd.111.039164. Epub 2011 Jul 13.

PMID:
21752943
[PubMed - indexed for MEDLINE]
Free Article
4.

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.

Kraus M, Bader J, Overkleeft H, Driessen C.

Blood Cancer J. 2013 Mar 1;3:e103. doi: 10.1038/bcj.2013.2.

PMID:
23454896
[PubMed]
Free PMC Article
5.

Carfilzomib: a novel agent for multiple myeloma.

Redic K.

J Pharm Pharmacol. 2013 Aug;65(8):1095-106. doi: 10.1111/jphp.12072. Epub 2013 Apr 24. Review.

PMID:
23837578
[PubMed - indexed for MEDLINE]
6.

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma.

Fostier K, De Becker A, Schots R.

Onco Targets Ther. 2012;5:237-44. doi: 10.2147/OTT.S28911. Epub 2012 Sep 28.

PMID:
23055749
[PubMed]
Free PMC Article
7.

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.

Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R.

Leukemia. 2013 Aug;27(8):1707-14. doi: 10.1038/leu.2013.29. Epub 2013 Jan 31.

PMID:
23364621
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.

Thompson JL.

Ann Pharmacother. 2013 Jan;47(1):56-62. doi: 10.1345/aph.1R561. Epub 2013 Jan 8. Review.

PMID:
23300152
[PubMed - indexed for MEDLINE]
9.

Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.

Wang Z, Yang J, Kirk C, Fang Y, Alsina M, Badros A, Papadopoulos K, Wong A, Woo T, Bomba D, Li J, Infante JR.

Drug Metab Dispos. 2013 Jan;41(1):230-7. doi: 10.1124/dmd.112.047662. Epub 2012 Nov 1.

PMID:
23118326
[PubMed - indexed for MEDLINE]
Free Article
10.

Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).

Hájek R, Bryce R, Ro S, Klencke B, Ludwig H.

BMC Cancer. 2012 Sep 19;12:415. doi: 10.1186/1471-2407-12-415.

PMID:
22992303
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.

Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE.

Clin Cancer Res. 2012 Oct 15;18(20):5639-49. doi: 10.1158/1078-0432.CCR-12-1213. Epub 2012 Aug 28.

PMID:
22929803
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.

Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S.

Mol Cancer Ther. 2012 May;11(5):1122-32. doi: 10.1158/1535-7163.MCT-12-0021. Epub 2012 Mar 12.

PMID:
22411899
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M.

Br J Haematol. 2012 Sep;158(6):739-48. doi: 10.1111/j.1365-2141.2012.09232.x. Epub 2012 Jul 30.

PMID:
22845873
[PubMed - indexed for MEDLINE]
14.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ.

Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.

PMID:
17591945
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Acute kidney injury.

Bellomo R, Kellum JA, Ronco C.

Lancet. 2012 Aug 25;380(9843):756-66. doi: 10.1016/S0140-6736(11)61454-2. Epub 2012 May 21. Review.

PMID:
22617274
[PubMed - indexed for MEDLINE]
16.

Carfilzomib: a novel second-generation proteasome inhibitor.

Khan ML, Stewart AK.

Future Oncol. 2011 May;7(5):607-12. doi: 10.2217/fon.11.42.

PMID:
21568676
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Implications of acute functional injury following percutaneous renal artery intervention.

Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ, Lumsden AB.

Ann Vasc Surg. 2008 Nov;22(6):783-9. doi: 10.1016/j.avsg.2008.06.006. Epub 2008 Aug 9.

PMID:
18692990
[PubMed - indexed for MEDLINE]
18.
19.

Carfilzomib for the treatment of multiple myeloma.

Lue J, Goel S, Mazumder A.

Drugs Today (Barc). 2013 Mar;49(3):171-9. doi: 10.1358/dot.2013.49.3.1939264.

PMID:
23527321
[PubMed - indexed for MEDLINE]
20.

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.

Jain S, Diefenbach C, Zain J, O'Connor OA.

Core Evid. 2011;6:43-57. doi: 10.2147/CE.S13838. Epub 2011 Apr 4.

PMID:
21654882
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk